What an inspiring evening of innovation and collaboration! Last Thursday, Eagle IP was honored to once again host the American Intellectual Property Law Association (AIPLA) Women in IP Global Networking Event in Hong Kong, joining forces with hundreds of remarkable women across 40+ global cities.

In the spirit of this year’s theme “Innovation and Collaboration,” we gathered fellow female leaders, innovators, entrepreneurs and IP practitioners to share their amazing career journeys and lessons learnt along the way. We started off the evening with Jennifer Che and Pauli Wong, sharing their paths from scientists that transitioned into an IP career, and what it means to them now to support scientists as IP professionals. We were also privileged to have Dr. Cathy Jim, of RHT Industries Limited, share with us her inspiring journey as a Chemist and Entrepreneur. Cathy recounted how she and her team overcame many difficulties along their path to providing a better solution to real world air quality problems through science. Her one piece of advice and guiding principle? Resilience. At 8PM HKT, we promptly dialed into a joint video call to say hello to hundreds of women at 40+ participating cities around the world holding their own simultaneous events.

To all who joined us: thank you for your lively participation and sharing. Together, we’re not just shaping the future of innovation—we’re redefining what it means to lead. Here’s to many more years of collaboration, growth, and breaking barriers!

我們過去活動

Recommended Insights

Breaking: China Released New Implementation Measures for the New Patent Linkage System

2021年7月14日
On July 4, 2021, China’s National Medical Products Administration (NMPA) and the China National Intellectual Property Administration (CNIPA) released details on the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage”), effective July 4, 2021. Below is a summary highlighting key provisions and changes from the draft measures. Creation of an […]

Can Post Filing Data Overcome Inventive Step in China?

2018年11月19日
Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]

Foreigners Beware: China Proposes Requiring IP Made Using Exported Chinese Genetic Resources to be Co-Owned by Chinese Collaborators

2023年3月22日
Proposed Examination Guidelines for the New Chinese Patent Law – Topic 2: Genetic Resource Restriction How Will the Tightened Genetic Resource Restrictions Affect Your IP In 2019-2021, China’s Ministry of Science and Technology (“MOST”, or the Science Ministry) established several laws and regulations with respect to biosafety1 and human genetic resources management2 (collectively referred as […]

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

2023年12月12日
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]
Top crossarrow-right